+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 7 Actively Recruiting clinical trials

R

Actively Recruiting

Researchers are evaluating the effectiveness and safety of finerenone compared to a placebo in patients hospitalized with acute decompensated heart failure who have mildly reduced or preserved left ventricular ejection fraction. This international, randomized, double-blind, placebo-controlled Phase 3 trial aims to study how finerenone affects morbidity and mortality in these patients. Participants will be randomly assigned to receive either oral finerenone or a matching placebo. The study is event-driven and will monitor patients for up to approximately 30 months. It includes ongoing evaluation of heart failure events, cardiovascular death, and adverse events related to the study drug. Both groups will be observed throughout this period to compare outcomes. During the trial, participants will undergo regular assessments including monitoring for heart failure events, cardiovascular death, and serious adverse events. The study will also measure changes in symptom scores using the Kansas City Cardiomyopathy Questionnaire at 6 months. Safety and tolerability will be closely tracked, including adverse events leading to discontinuation of the study drug. Participants will be followed for up to 30 months to assess long-term effects.

Age: 18Years +All GendersPhase 3
356 locations
S

Actively Recruiting

Researchers are evaluating finerenone compared to a placebo to assess the effectiveness and safety of treatment in patients with heart failure and reduced ejection fraction HFrEF who cannot tolerate or are not eligible for steroidal mineralocorticoid receptor antagonists sMRA. This international study is a randomized, double-blind, placebo-controlled trial focused on this specific group of heart failure patients. Participants will be randomly assigned to receive either oral finerenone or a matching placebo. The study uses a parallel design and treatment will be monitored for up to about 30 months. During this time, researchers will track cardiovascular events, heart failure events, and any serious or adverse events leading to discontinuation of the study drug. Throughout the study, participants will undergo regular assessments including symptom questionnaires and monitoring for cardiovascular outcomes and safety. The main outcomes include the time to the first cardiovascular death or heart failure event and the number of serious adverse events. The study also tracks changes in symptom scores over six months and overall survival. Participants will be followed closely during treatment and after to understand both efficacy and safety.

Age: 18Years +All GendersPhase 3
176 locations
E

Actively Recruiting

Researchers are investigating adults in Sri Lanka with heart failure with reduced ejection fraction HFrEF to assess how an HFrEF polypill strategy affects the combined rate of cardiovascular death and repeated heart failure hospitalizations compared to usual care. The study evaluates this over at least 12 months of follow-up and includes secondary outcomes such as mortality rates, heart function changes via echocardiogram, and quality of life measures. Participants will be randomly assigned to two groups one receives usual care with guideline-directed medications dispensed at no charge when available, while the other receives a combined polypill containing bisoprolol, losartan, eplerenone, and dapagliflozin in three possible dose strengths. The polypill dose will be adjusted during scheduled visits to reach the highest tolerated dose, aiming for the strongest dose by study end. During the study, participants undergo regular visits at 1, 3, 6, 9, and 12 months and every 3 months thereafter, averaging 18 months total. Researchers will monitor heart function, biomarker levels, quality of life questionnaires, medication adherence, and safety outcomes including adverse events and laboratory measures like potassium and creatinine levels. The study includes detailed assessments to evaluate treatment persistence, dose optimization, and overall health impact over time.

Age: 18Years +All GendersPhase 3
12 locations
S

Actively Recruiting

The ICU-related Out-of-Pocket Expenses ICOPE study is a multinational, prospective observational study conducted in African and Asian countries to understand the financial impact of ICU care on patients and their families. The study focuses on measuring out-of-pocket expenses and the occurrence of catastrophic health expenditure among patients who stay in the ICU for more than 24 hours, including those who receive mechanical ventilation and those who do not. The study addresses the rising cost burden related to ICU care in low- and middle-income countries LMICs and aims to identify factors contributing to financial hardship. Participants include all patients admitted to participating ICUs during a 14-day recruitment period, with a planned sample size of at least 354 patients. The study compares groups of patients receiving invasive mechanical ventilation with those who do not, tracking their ICU-related expenses. The follow-up period extends from ICU admission to discharge, with additional assessments at 30 days and 6 months, spanning a total study duration of 18 months. During the study, researchers will collect detailed information about direct and indirect costs associated with ICU care, including medical and non-medical expenses. They will also examine how families cope with these costs and identify risk factors for catastrophic health expenditure. The primary outcomes include out-of-pocket cost per patient episode and the relative risk of catastrophic health expenditure by ICU discharge. Secondary outcomes include risk factors for catastrophic expenditure and the frequency of various coping strategies used by families.

All AgesAll Genders
44 locations
S

Actively Recruiting

Researchers are evaluating the effects of the SGLT2 inhibitor dapagliflozin compared to metformin on the annual decline in kidney function, measured by eGFR, in people with Type 2 Diabetes. This Phase 3, randomized, double-blind trial is conducted in primary care and community sites in Australia and tertiary care centers in Sri Lanka. The purpose is to understand which first-line therapy may better prevent kidney decline in this population. After a 4-week active run-in period, participants will be randomly assigned to one of two groups one group will take dapagliflozin 10 mg once daily with placebo metformin tablets, and the other group will take metformin XR 2000 mg once daily with placebo dapagliflozin tablets. Treatment will continue for 2 years under quadruple masking to maintain study integrity. During the study, participants will undergo assessments including kidney function tests eGFR, serum creatinine, urine albumin creatinine ratio, blood sugar measurements HbA1C, fasting glucose, blood pressure monitoring, body weight check, and quality of life evaluations using the EQ-5D-5L. Mental health symptoms such as anxiety and depression will also be measured with the HADS questionnaire. The primary outcome is the rate of eGFR decline over 24 months, with safety and other health indicators monitored throughout the study period.

Age: 18Years +All GendersPhase 3
8 locations
S

Actively Recruiting

Researchers are studying the safety, effectiveness, and how the body processes the investigational drug WAL0921 in adults with various glomerular kidney diseases and proteinuria. These include diabetic nephropathy and rare conditions such as primary focal segmental glomerulosclerosis, treatment-resistant minimal change disease, primary immunoglobulin A nephropathy, and primary membranous nephropathy. This is a Phase 2, randomized, double-blind, placebo-controlled study conducted at multiple centers to evaluate WAL0921 compared to a placebo. Participants will be randomly assigned to receive either the investigational drug WAL0921 or a placebo through an intravenous infusion every two weeks for a total of seven infusions. The study includes a treatment period followed by a 24-week follow-up after the last infusion to monitor participants. The treatments are given in parallel groups to compare their effects and safety. During the study, participants will undergo regular assessments including monitoring for adverse events from the start through Week 36. Researchers will also measure changes in albuminuria, proteinuria, and kidney function markers such as estimated glomerular filtration rate over 24 weeks. These evaluations help determine how the drug affects kidney disease markers and overall safety. The total participation time includes treatment and follow-up periods lasting several months.

Age: 18Years - 75YearsAll GendersPhase 2
50 locations
C

Actively Recruiting

Researchers are conducting an international, multi-center Phase III trial called CAPTIVATE to study treatments for chronic kidney disease CKD, which affects over 800 million people worldwide and can lead to kidney failure and other serious health problems. The trial aims to identify the best single or combined treatments that can slow CKD progression and reduce the number of people developing kidney failure. CAPTIVATE uses an adaptive platform design allowing multiple therapies to be tested efficiently within a common framework, with the flexibility to add or remove treatments over time. Participants may join one or more treatment domains and receive each study treatment for 2 years. Treatments under study include finerenone tablets taken once daily and semaglutide injections given once weekly, along with their matching placebos. Participants will attend scheduled study visits at approximately 1 month, 3 months, 6 months, 12 months, 18 months, and 2 years after starting treatment, with a final visit one month after treatment ends. The trial is ongoing and will continue recruiting for several years. During the study, participants undergo blood and urine tests, safety checks, and assessments of treatment adherence at regular visits. The research team collects information on overall health status every 5 years. The primary outcomes focus on treatment effects measured from randomization through week 108, with various secondary outcomes tracked throughout the study. Safety is monitored continuously, and participants remain under their usual care alongside the trial procedures.

Age: 18Years +All GendersPhase 3
51 locations